Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors

Journal of Urology

Volumn 165, Issue 5 I, 2001, Pages 1488-1491

  Palou, J ^a,b   Laguna, P ^a,b   Millan Rodriguez F ^a,b   Hall, R R ^a,b   Salvador Bayarri, J ^a,b   Vicente Rodriguez J ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b NONE

Author keywords

BCG vaccine; Bladder; Bladder neoplasms; Carcinoma, transitional cell; Immunotherapy

Indexed keywords

BCG VACCINE; MITOMYCIN;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; BLADDER CONTRACTION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTECTOMY; DRUG EFFICACY; DRUG INSTILLATION; FEMALE; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0035047153     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-5347(05)66333-1     Document Type: Article

References (23)

1. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer
2. Multivariate analysis of the prognostic factors of primary superficial bladder cancer
3. Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors
4. Nonspecific immunotherapy with BCG vaccine in bladder tumors: A preliminary report
5. Bacillus Calmette-Güerin versus doxorubicin versus thiotepa: A randomized prospective study in 202 patients with superficial bladder cancer
6. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder
7. Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer
8. Single course versus maintenance bacillus Calmette-Guérin therapy for superficial bladder tumors: A prospective, randomized trial
9. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer
10. Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results
11. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder
12. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group study
13. Carcinoma in situ
14. Primary bladder carcinoma in situ: Assessment of early BCG response as a prognostic factor
15. Bacillus Calmette-Guérin immunotherapy of superficial bladder cancer
16. Long term follow up of an EORTC randomized prospective trial comparing intravesical bacillus Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer
17. Long-term results of intravesical bacillus Calmette-Güerin therapy for superficial bladder cancer
18. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer
19. Urinary cytokines during intravesical bacillus Calmette-Guèrin therapy for superficial bladder cancer: Processing, stability and prognostic value
20. Depressed proliferative responses in patients treated with 12 weeks of intravesical BCG
21. What is the optimal regimen for BCG Intravesical therapy? Are six weekly instillations necessary?
22. Effects of local bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall
23. Clinical prognostic factors of recurrence and progression in TCC stage T1G3 treated with BCG